Company Overview and News

10
Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options

13h zacks
Investors in TG Therapeutics, Inc. (TGTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $12.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
EVLV TGTX MLAB

7
TGTX / TG Therapeutics, Inc. null

2018-09-19 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A
TGTX

7
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y [email protected] [email protected],C
TGTX

8
TGTX / TG Therapeutics, Inc. null

2018-08-22 sec.gov - 1
 
TGTX

9
Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?

2018-08-20 zacks - 2
Investors in TG Therapeutics, Inc. (TGTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $18 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
TGTX

10
TG Therapeutics Is Worth A Look Before Phase 3 Combination Cancer Data

2018-08-18 seekingalpha - 3
TG Therapeutics expects to report phase 3 cancer data next month from its study using TG-1101 (ublituximab) and TGR-1202 (umbralisib) to treat patients with first-line r/r chronic lymphocytic leukemia.
TGTX

13
Checkpoint Therapeutics: Potential For A Near-Term Run Up

2018-08-14 seekingalpha - 3
Shares have fallen by around 60% since the company´s common stock made its way onto the Nasdaq.
AZN TGTX AZN NHLD CKPT FBIO CLVS

8
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results

2018-08-07 globenewswire - 1
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2018 and recent company developments.
TGTX

7
TG Therapeutics Announces Completion of Target Enrollment in the ULTIMATE Phase 3 Trials in Multiple Sclerosis

2018-08-07 globenewswire
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in patients with relapsing forms of Multiple Sclerosis (RMS).
TGTX

8
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2018 Financial Results and Business Update

2018-08-06 globenewswire - 1
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Tuesday, August 7, 2018 at 4:30pm ET to discuss results for the second quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call.
TGTX

24
Fortress Biotech: Highly Complex, Greatly Undervalued

2018-07-17 seekingalpha - 1
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.
MBIO FBIOP TGTX AAV TEVA CKPT TBI CNLM TEVVF FBIO OACQ ATXI OACQW TEVJF OACQU OACQR NHLD

64
Oncolix, Inc. Forms Scientific and Clinical Advisory Board and Appoints First Member

2018-07-17 accesswire - 1
HOUSTON, TX / ACCESSWIRE / July 17, 2018 / Oncolix, Inc. (OTCQB: ONCX) (the "Company"), a biotechnology company focused on gynecological cancers, announced that the Company has appointed Robert Niecestro, PhD as its first member of its Regulatory Strategy, Scientific and Clinical Advisory Board.
ATXI AXSM TGTX KERX CKPT CTXR

7
TGTX / TG Therapeutics, Inc. / LFB Biotechnologies S.A.S.U. - SC 13D/A (Activist Investment)

2018-07-11 sec.gov
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TGTX

TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 88322Q108